Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDN-OL1
- Development stage
- Discontinued
- Lead developer
- Edunn Biotechnology
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
EDN-OL1 is a patented antisense phosphorothioate oligonucleotide developed by Edunn Biotechnology for the treatment of Alzheimer's disease and CNS symptoms associated with Down syndrome. The drug is designed to cross the blood-brain barrier following intravenous administration. Its mechanism of action involves targeting the amyloid precursor protein (APP) mRNA to reduce the production of APP and subsequent amyloid-beta proteins. In preclinical murine models, EDN-OL1 demonstrated the ability to restore cognitive function and potentially halt or decrease the rate of cognitive decline. Development was previously supported through a collaboration with the National Center for Advancing Translational Sciences (NCATS), which has since concluded due to a change in the company's business strategy.
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on EDN-OL1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDN-OL1.